Altria's Q2 Earnings on the Deck: How to Play the Stock

Altria (MO) is poised to report Q2 2025 earnings on July 30, with the Zacks Consensus Estimate projecting a 4.6% EPS increase to $1.37 despite a 1.7% revenue decline to $5.2 billion, and a model-predicted earnings beat. The company faces significant challenges from the NJOY ACE exclusion order and ongoing cigarette volume pressure, but is expected to mitigate these through strong pricing power, disciplined cost controls, and margin expansion. Despite a mixed operational backdrop, Altria’s stock exhibits relative stability and trades at an appealing forward P/E of 10.96, a discount to its industry and many competitors, suggesting cautious optimism for investors.

Analysis

Altria Group faces a bifurcated outlook heading into its second-quarter 2025 earnings report. Consensus estimates project a 1.7% year-over-year revenue decline to $5.2 billion, directly reflecting significant operational headwinds. These pressures are twofold: first, the complete halt of NJOY ACE shipments following an ITC exclusion order, which removes the company's sole FDA-authorized e-vapor product and impairs its smoke-free strategy; and second, continued volume declines in the core cigarette segment driven by macroeconomic strain and competition from illicit vapes. Despite these top-line challenges, the bottom line is forecast to grow, with consensus EPS at $1.37, representing a 4.6% increase. This expected profitability is attributed to robust pricing power, particularly on the Marlboro brand, disciplined cost management through initiatives like 'Optimize & Accelerate,' and anticipated margin expansion. The Zacks model reinforces this positive earnings outlook, predicting a beat based on a positive Earnings ESP of +1.03%. From a market perspective, Altria's stock has advanced 2.6% over the past three months, trailing the S&P 500's 15.5% gain but performing in line with its industry. Critically, the stock presents a compelling valuation case, trading at a forward P/E of 10.96, a significant discount to the industry average of 14.48 and peers such as Philip Morris International.

Key Decisions for Investors

• Investors should weigh the material risk from the NJOY ACE regulatory exclusion and persistent cigarette volume declines against the firm's demonstrated ability to protect profitability through aggressive pricing and cost controls.
• Given the stock's valuation at a forward P/E of 10.96, which is a notable discount to the industry, value-focused investors may find the current level an attractive entry point, contingent on management's continued execution on margin expansion.
• Ahead of the July 30 earnings call, it is critical to monitor management's commentary for any updates on the smoke-free product pipeline and the viability of its long-term strategy post-NJOY.
• While the stock offers relative stability and a potential earnings beat, its significant underperformance against the broader market and faster-growing peers suggests capital appreciation may remain constrained until a clear growth catalyst emerges.